Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)
Vir Biotechnology (VIR) posted Preferred Stock Liabilities of $636.6 million for Q3 2019, little changed sequentially from $636.6 million in Q2 2019, and up 105.93% YoY from $309.1 million in Q3 2018.
Powered by 
Analysis
Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Vir Biotechnology has reported Preferred Stock Liabilities for 2 years, with the latest figure at $636.6 million in Q3 2019.
- Quarterly Preferred Stock Liabilities rose 105.93% year-over-year to $636.6 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $636.6 million (up 105.93% YoY) and the FY2018 annual result came in at $309.1 million, up 5.68% from the prior year.
- Preferred Stock Liabilities steadied at $636.6 million in Q3 2019 per VIR's latest filing, from $636.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $636.6 million in Q2 2019 and troughed at $309.1 million in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vir Biotechnology | 1.92 Bn | 1.92 Bn | 238.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 636.61 Mn |
| Jun 30, 2019 | 636.61 Mn |
| Dec 31, 2018 | 309.14 Mn |
| Sep 30, 2018 | 309.14 Mn |